Locally, most providers utilize a panel that measures acute serologic markers for hepatitis A, B, and C as screening prior to rituximab; this panel only captures HBsAg and anti-HBcAb IgM, which do not constitute adequate screening for chronic or past infection. This evidence concerns the gene CD40LG and hepatitis A virus infection.